Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | ALDH1A3 | P47895 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.36 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29723741 | 1.00 | ALDH1A1 (0.64) | ALDH1A1VCAM1ALDH1A3HSD17B10ALDH3A1 | |
| SCHEMBL23604537 | 0.84 | ALDH1A1 (0.50) | ALDH1A1VCAM1ALDH1A3HSD17B10ALDH3A1 | |
| SCHEMBL1572335 | 0.82 | ALDH1A1 (0.64) | ALDH1A1VCAM1ALDH1A3HSD17B10ALDH3A1 | |
| SCHEMBL18346095 | 0.79 | XDH (0.48) | ALDH1A1VCAM1KDM4ERAB9ATDP1 | |
| SCHEMBL18346097 | 0.79 | XDH (0.48) | ALDH1A1VCAM1KDM4ERAB9ATDP1 | |
| SCHEMBL29364412 | 0.78 | ALDH1A1 (1.00) | ALDH1A1VCAM1ALDH1A3HSD17B10ALDH3A1 | |
| SCHEMBL48577 | 0.78 | ALDH1A1 (1.00) | ALDH1A1VCAM1ALDH1A3HSD17B10ALDH3A1 | |
| SCHEMBL29610150 | 0.78 | ALDH1A3 (0.52) | ALDH1A1ALDH1A3HSD17B10ALDH3A1KDM4E | |
| SCHEMBL870202 | 0.78 | ALDH1A3 (0.52) | ALDH1A1ALDH1A3HSD17B10ALDH3A1KDM4E | |
| SCHEMBL16959164 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KDM4ERAB9ATSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569553-A | Preparation method and application of 3-methoxy-4-chlorobenzaldehyde | 苏州亚科科技股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| WO-2026107424-A1 | N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| CN-119569553-B | Preparation method and application of 3-methoxy-4-chlorobenzaldehyde | 苏州亚科科技股份有限公司 | 2026-04-21 | — | — | CN | disclosed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-3483142-B1 | AROMATIC ACETYLENE OR AROMATIC ETHYLENE COMPOUND, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING MAXINOVEL PHARMACEUTICALS CO LTD (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-24 | — | — | US | disclosed |
| WO-2001083484-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| US-6162918-A | Xanthene and acridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-5969139-A | INHIBITORS OF HERPES SIMPLEX VIRUS THYMIDINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 1999-10-19 | — | — | US | disclosed |
| CN-1228778-A | Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists | MERZ & CO GMBH & CO (DE) | 1999-09-15 | — | — | CN | disclosed |
| WO-1999038833-A1 | PROCESS FOR THE HALOGENATION OF ALDEHYDES AND KETONES | BROMINE COMPOUNDS LTD. (IL) | 1999-08-05 | — | — | WO | disclosed |
| EP-0931081-A1 | PYRIDAZINO 4,5-B]-QUINOLINE 5-OXIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS GLYCINE ANTAGONISTS | MERZ + CO. GmbH & Co. (DE) | 1999-07-28 | — | — | EP | disclosed |
| EP-0823426-A1 | Xanthene and acridine derivatives and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-02-11 | — | — | EP | disclosed |
| WO-1998004556-A1 | PYRIDAZINO [4,5-B]-QUINOLINE 5-OXIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS GLYCINE ANTAGONISTS | MERZ + CO. GMBH & CO. (DE) | 1998-02-05 | — | — | WO | disclosed |
| EP-0074571-A1 | Process for the preparation of para-substituted 3-bromobenzaldehydes | BAYER AG (DE) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612396-B1 | Modulators of beta catenin and uses thereof | CTNNB1, CTNND1, CTNNA1 | ALDH1A1 3860/4885VCAM1 3466/4885ALDH1A3 4129/4885 |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885VCAM1 3606/4885ALDH1A3 3176/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | ALDH1A1 1178/4885VCAM1 1293/4885ALDH1A3 1288/4885 |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | ALDH1A1 3860/4885VCAM1 3466/4885ALDH1A3 4129/4885 |
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | ALDH1A1 3232/4885VCAM1 1912/4885ALDH1A3 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.